Prognostic markers in rectal carcinoma

Seminars in Surgical Oncology

Volumn 15, Issue 2, 1998, Pages 131-140

  Jessup, J Milburn ^a   Loda, Massimo ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; Adenocarcinoma; Biological tumor markers; Carcinoembryonic antigen; Cell cycle proteins; Chromosome deletion; Colorectal neoplasms genetics; Cyclins; Immunohistochemistry; Laminin; Lectins; Mucins; Mutation; Neoplasm antigens; Neoplasm staging; Nuclear proteins; Oncogenes; Ploides; Prognosis; Rectal neoplasms genetics; Statistics; Sucrase isomaltase complex; Survival analysis; Thymidylate synthase; Tumor suppressor genes

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; LAMININ; MUCIN; OLIGO 1,6 GLUCOSIDASE; PROTEIN P53; REGULATOR PROTEIN; SUCRASE; THYMIDYLATE SYNTHASE;

CELL PROLIFERATION; DNA CONTENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECTUM CARCINOMA; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DCC; GENES, P53; HUMANS; PLOIDIES; PROGNOSIS; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031840971     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199809)15:2<131::AID-SSU11>3.0.CO;2-5     Document Type: Review

References (83)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Kim DG, Madoff RD: Transanal treatment of rectal cancer: ablative methods and open resection. Semin Surg Oncol 1998; 15:101-113.
3. Busse PM, Ng A, Recht A: Induction therapy for rectal carcinoma. Semin Surg Oncol 1998;15:120-125.
4. Fisher ER, Robinsky B, Sass R, Fisher B: Relative prognostic value of the Dukes and the Jass systems in rectal cancer. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01) [comment in: Dis Colon Rectum 1990;33:721-722]. Dis Colon Rectum 1989;32:944-949.
5. Jass JR, Atkin WS, Cuzick J, et al: The grading of rectal cancer: historical perspectives and a muitivariate analysis of 447 cases. Histopathology 1986;10:437-459.
6. Henson DE, Fielding P, Grignon DJ, et al: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary [Review]. Arch Pathol Lab Med 1995;119:1109-1112.
7. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology [comment in J Clin Oncol 1997;15:863-864]. J Clin Oncol 1996;14:2843-2877.
8. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers [Review][comment in J Natl Cancer Inst 1996;88:1419-1420]. J Natl Cancer Inst 1996;88:1456-1466.
9. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
10. Jessup J, Steele G, Thomas P, et al: Molecular biology of neoplastic transformation of large bowel: Identification of two pathways. Surg Oncol Clin N Am 1994;3:449-477.
11. Vogelstein B, Fearon ER, Kern SE, et al: Allellotype of colorectal carcinomas. Science 1989;244(4901):207-211.
12. Yin Y, Tainsky MA, Bischoff FZ, et al: Wild-type p53 restores cell cycle control and inhibits sene amplification in cells with mutant p53 alleles. Cell 1992;70:937-948.
13. Shaw P, Tardy S, Benito E, et al. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene 1991;6:2121-2128.
14. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17p deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244(4901):217-221
15. Kastrinakis WV, Ramchurren N, Rieger KM, et al: Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995;11:647-652
16. 1[editorial][comment in J Pathol 1995;175:93-95]. J Pathol 1994;172:1-4.
17. Fearon ER, Cho KR, Nigro JM, et al: Identification of a chromosome 18q gene which is altered in colorectal cancers. Science 1990;247(4938):49-56.
18. Kern SE, Fearon ER, Tersmette KW, et al: Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected: published erratum appears in JAMA 1989;262:1952]. JAMA 1989;261:3099-3103.
19. O'Connell MJ, Schaid DJ, Ganju V, et al: Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis? Cancer 1992;70(6 Suppl):1732-1739.
20. Laurent-Puig P, Olschwang S, Delattre O, et al: Survival and acquired genetic alterations in colorectal cancer [comment in Gastroenterology 1992;102(4 Pt 2):1419-1421]. Gastroenterology 1992;102(4 Pt 2):1136-1141.
21. Zetter BR: Adhesion molecules in tumor metastasis [Review] [comment in Semin Cancer Biol 1993;4:215-218]. Semin Cancer Biol 1993;4:219-229.
22. Jen J, Kim H, Piantadosi S, et al: Allelic loss of chromosome 18q and prosnosis in colorectal cancer [comment in N Engl J Med 1994;331:267-268; N Engl J Med 1994;331:1591-1592]. N Engl J Med 1994;331:213-221.
23. Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate rumor suppressor gene at human chromosome 18q21.1 [comment in Science 1996;271(5247);294]. Science 1996;271(5247):350-353.
24. Eppert K, Scherer SW, Ozcelik H, et al: MADR2 maps to 18q21 and encodes aTGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-552.
25. Shibata D, Reale Ma, Lavin P, et al: The DCC protein and prognosis in colorectal cancer [comment in N Engl J Med 1997;336:1456-1457]. N Engl J Med 1996;335:1727-1732.
26. Bell SM, Scott N, Cross D, et al: Prognostic value of p53 overexpression and ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
27. Finklestein SD, Sayegh R, Bakker A, Swalsky P: Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-532.
28. Lazaris AC, Davaris P, Nakopoulou L, et al: Correlation between immunohistochemical expression of proliferating cell nuclear antigen and flow cytometry parameters in colorectal neoplasia. Dis Colon Rectum 1994;37:1083-1089.
29. Neoptolemos JP, Oates GD, Newbold KM, et al: Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes' or Jass' classifications for colorectal cancer. Br J Surg 1995;82:184-187.
30. Willett CG, Warland G, Cheek R, et al: Proliferating cell nuclear antigen in rectal cancer: predictor of response to preoperative irradiation. J Clin Oncol 1994;12:679-682.
31. Willett CG, Warland G, Coen J, et al: Rectal cancer: The influence of tumor proliferation on response to preoperative irradiation. Int J Radiat Oncol Biol Phys 1995;32:57-61.
32. Willett CG, Warland G, Hagan MP, et al: Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 1995;13:1417-1424.
33. Desai GR, Myerson RJ, Higashikubo R, et al: Carcinoma of the rectum. Possible cellular predictors of metastatic potential and response to radiation therapy. Dis Colon Rectum 1996;39:1090-1096.
34. Arber N, Hibshoosh H, Moss SF, et al: Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-674.
35. Bartkova J, Lukas J, Strauss M, Bartek J: The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 1994;58:568-573.
36. Yasui W, Kuniyashi H, Yokozaki H, et al: Expression of cyclin E in colorectal adenomas and adenocarcinomas: Correlation with expression of Ki-67 antigen and p53 protein. Virchows Arch 1996;429:13-19.
37. Kitahara K, Yasui W, Kuniyasu H, et al: Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995;62:25-28.
38. Steeg PS, Abrahms JS: Cancer prognostics: past, present and p27 [news] [comment in Nat Med 1997;3:222-225, 227-230,231-234]. Nat Med 1997;3:152-154.
39. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 [comment in Science 1995; 269(5224):631-632]. Science 1995;269(5224):682-685.
40. Loda M, Cukor B, Tam SW, et al: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas [comment in Nat Med 1997;3:152-154]. Nat Med 1997;3:231-234.
41. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients [comment in Nat Med 1997;3:152-154] Nat Med 1997;3:222-225.
42. St. Croix B, Florenes VA, Rak JW, et al: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-1210.
43. Ishii S, Steele G Jr, Ford R, et al: Normal colonic epithelium adheres to carcinoembryonic antigen and type IV collagen [comment in Gastroenterology 1994;106:1378-1382]. Gastroenterology 1994;106:1242-1250.
44. Jessup JM, Gallick GE: The biology of colorectal carcinoma [Review]. Curr Probl Cancer 1992;16:261-328.
45. Lee EC, Woo HJ, Korzelius CA, et al: Carbohydrate-binding protein 35 is the major cell-surface laminin-binding protein in colon carcinoma. Arch Surg 1991;126:1498-1502.
46. Ohannesian DW, Lotan D, Thomas P, et al: Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 1995;55:2191-2199.
47. Irimura T, Matsushita Y, Sutton RC, et al: Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991;51:387-393.
48. Schoeppner HL, Raz A, Ho SB, Bresalier RS: Expression of an endogenous galactose-binding lectine correlates with neoplastic progression in the colon. Cancer 1995;75:2818-2826.
49. Lise M, Loda M, Fiorentino M, et al: Association between sucrase-isomaltase and p53 expression in colorectal cancer. Ann Surg Oncol 1997;4:176-183.
50. Bresalier RS, Ho SB, Schoeppner HL, et al: Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 1996;110:1354-1367.
51. Varki A: Selectins and other mammalian sialic acid-binding lectins [Review]. Curr Opin Cell Biol 1992;4:257-266.
52. Itzkowitz SH, Yuan M, Montgomery CK, et al: Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197-204.
53. Itzkowitz SH, Bloom EJ, Kokal WA, et al: Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66:1960-1966.
54. x antigen in relation to survival of patients with colorectal carcinoma. Cancer 1993;72:2323-2330.
55. x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993;53:3632-3637.
56. Andrews CW Jr, Jessup JM, Goldman H, et al: Localization of tumor-associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon. Cancer 1993;72:3185-3190.
57. Wiltz O, O'Hara CJ, Steele GD, Mercurio AM: Sucrase-isomaltase: a marker associated with the progression of adenomatous polyps to adenocarcinomas [published erratum in Surgery 1991;102:232]. Surgery 1990;108:269-276.
58. Wiltz O, O'Hara CJ, Steele GD Jr, Mercurio AM: Expression of enzymatically active sucrase-isomaltase is a ubiquitous property of colon adenocarcinomas. Gastroenterology 1991;200:1266-1278.
59. Jessup JM, Lavin PT, Andrews CW Jr, et al: Sucrase-isomaltase is an independent prognostic marker for colorectal carcinoma. Dis Colon Rectum 1995;38-1257-1264.
60. Johnston PG, Allegra CJ: Colorectal cancer biology: clinical implications [Review]. Semin Oncol 1995;22:418-432.
61. Chu E, Allegra CJ: The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul 1996;36:143-163.
62. Copur S, Aiba K, Drake JC, et al: Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995;49-1419-1426.
63. Mulder NH, Timmer-Bosscha H, Meersma GJ, Verschueren RC: Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer. Anticancer Res 1994;14:2677-2680.
64. Peters GJ, van der Wilt CL, van Groeningen CJ, et al: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-2042.
65. Leichman L, Lenz HJ, Leichman CG, et al: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995;31A:1306-1310.
66. Sanguedolce R, Brumarescu I, Dardanoni G, et al: Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer, a preliminary study. Anticancer Res 1995;15:901-906.
67. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
68. Lenz HJ, Danenberg KD, Danenberg P, et al p53 status and thymidylate synthase (TS) expression are associated and predict for recurrence in patients with stage II colon cancer (CC) [Abstract]. Proc Am Soc Clin Oncol 1996;15:215.
69. Nakamori S, Watanabe H, Kameyama M, et al: Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer 1994;74:1855-1862.
70. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkins lymphomas in humans. Br J Cancer 1996;73:1401-1408.
71. Liabakk NB, Talbot I, Smith RA, et al: Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56:190-196.
72. Grigioni WF, D'Errico A, Fiorentino M, et al: Gelatinase A (MMP-2) and its mRNA detection in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. Diagn Mol Pathol 1994;3:163-169.
73. Grigioni WF, D'Errico A, Fortunato C, et al: Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol 1994;7:220-225.
74. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339(6219):58-61.
75. Ribatti D, Vacea A, Palmer W, et al: Angiogensis during tumor progression in human malignant melanoma. In Steiner R, Weisz PB, Langer R (eds): "Angiogenisis: Key principles -science, technology, medicine." Basel: Birkhauser Verlag; 1992. p. 415-419.
76. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast cancer. N Engl J Med 1991;324:1-8.
77. Saclarides TJ, Speziale NJ, Drab E, et al: Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 1994;37:921-926.
78. Frank RE, Saclarides TJ, Leurgans S, et al: Tumor angiogenesis as a predictor of recurrence and survival in node-negative colon cancer [comment in Ann Surg 1995;222:693-694]. Ann Surg 1995;222:695-699.
79. Takebayashi Y, Aklyama S, Yamada K, et al: Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996;78-226-231.
80. Engel CJ, Bennett ST, Chambers AF, et al: Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996;20:1260-1265.
81. Bossi P, Viale, Lee AK, et al: Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 1995;55:5049-5053.
82. Mooteri S, Rubin D, Leurgens S, et al: Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum 1996;39:1073-1080.
83. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group [comment in Lancet 1994;343(8907):472-474]. Lancet 1994; 343(8907):1177-1183.